Developing a blood- based method to montior chemotherapeutic response
Research type
Research Study
Full title
A novel high-throughput approach to stratify patients based on chemotherapeutic response.
IRAS ID
223657
Contact name
Gareth Jenkins
Contact email
Sponsor organisation
Swansea University
Duration of Study in the UK
4 years, 11 months, 31 days
Research summary
We are interested in developing novel blood tests to monitor tumour response to chemo/ radio therapy in upper Gastrointestinal tract cancer patients. We would be looking to recruit patients from Singleton Hospital oncology department. Each patient would be invited to provide a blood sample before any treatment is undertaken and then at follow up appointments during their treatment.
Our test measures blood cell mutations, we have shown cancer patients have more mutated cells than non-cancer patients. The aim of the study is to correlate the response of the cancers (treatment responding v non- responding) with blood borne mutation levels and questionnaire results.
We would like to answer the following question:
Does the PigA mutation test show higher levels of mutations in cancer patients with a greater tumour response to chemo/radio therapy than in patients with limited tumour response?REC name
HSC REC A
REC reference
17/NI/0055
Date of REC Opinion
4 Apr 2017
REC opinion
Further Information Favourable Opinion